Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Lemtrada
Pharma
NICE gives a thumbs-down to Bristol Myers' MS newcomer Zeposia
NICE said it struggled to see how the benefits of Zeposia justify its cost, citing a lack of data comparing it to rival MS drugs like Roche’s Ocrevus.
Arlene Weintraub
Jan 22, 2021 11:21am
Sanofi ponies up $315M to settle Lemtrada milestone spat
Nov 4, 2019 10:30am
Sanofi's Lemtrada goes under EU review for fatal side effects
Apr 15, 2019 11:35am
Merck KGaA finally chalks up FDA nod for MS med Mavenclad
Apr 1, 2019 10:20am
FDA hits Sanofi's struggling Lemtrada with new safety warning
Nov 30, 2018 10:48am
Can Sanofi's new long-term Lemtrada data amp up MS sales?
Oct 11, 2018 9:59am